Frailty, mycophenolate reduction, and graft loss in kidney transplant recipients

Transplantation

Volumn 99, Issue 4, 2015, Pages 805-810

  McAdams Demarco, Mara A ^a,b   Law, Andrew ^a   Tan, Jingwen ^a   Delp, Cassandra ^a   King, Elizabeth A ^a,b   Orandi, Babak ^a,b   Salter, Megan ^a,b   Alachkar, Nada ^a   Desai, Niraj ^a   Grams, Morgan ^a,b   Walston, Jeremy ^a   Segev, Dorry L ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; IMMUNOSUPPRESSIVE AGENT;

ADULT; AFRICAN AMERICAN; AGE; ARTICLE; BODY MASS; CADAVER DONOR; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; FRAILTY; GRAFT FAILURE; HUMAN; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; PHYSICAL DISABILITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RACE DIFFERENCE; SEX DIFFERENCE; ADVERSE EFFECTS; AGED; ANALOGS AND DERIVATIVES; DOSE CALCULATION; DRUG EFFECTS; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HEALTH STATUS; IMMUNOLOGY; MARYLAND; MIDDLE AGED; PHENOTYPE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; TIME FACTOR; TREATMENT OUTCOME;

ADULT; AGED; BALTIMORE; DRUG DOSAGE CALCULATIONS; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HEALTH STATUS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PHENOTYPE; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK FACTORS; TIME FACTORS; TRANSPLANT RECIPIENTS; TREATMENT OUTCOME;

EID: 84930181105     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0000000000000444     Document Type: Article

References (30)

1. Maripuri S, Kasiske BL. The role of mycophenolate mofetil in kidney transplantation revisited. Transplant Rev (Orlando). 2014;28:26.
2. Pelletier RP, Akin B, Henry ML, et al. The impact of mycophenolate mofetil dosing patterns on clinical outcome after renal transplantation. Clin Transplant. 2003;17:200.
3. Knoll GA, MacDonald I, Khan A, et al. Mycophenolate mofetil dose reduction and the risk of acute rejection after renal transplantation. J Am Soc Nephrol. 2003;14:2381.
4. Kahu J, Kyllonen L, Salmela K. Impact of mycophenolate mofetil intolerance on early results of kidney transplantation. Transplant Proc. 2005;37:3276.
5. Ortega F, Sanchez-Fructuoso A, Cruzado JM, et al. Gastrointestinal quality of life improvement of renal transplant recipients converted from mycophenolate mofetil to enteric-coated mycophenolate sodium drugs or agents: mycophenolate mofetil and enteric-coated mycophenolate sodium. Transplantation. 2011;92:426.
6. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci. 2001;56:M146.
7. Garonzik-Wang JM, Govindan P, Grinnan JW, et al. Frailty and delayed graft function in kidney transplant recipients. Arch Surg. 2012;147:190.
8. McAdams-DeMarco MA, Law A, Salter ML, et al. Frailty and early hospital readmission after kidney transplantation. Am J Transplant. 2013;13:2091.
9. Waits SA, Kim EK, Terjimanian MN, et al. Morphometric age and mortality after liver transplant. JAMA Surg. 2014;149:335.
10. Walston J, Fried LP. Frailty and the older man. Med Clin North Am. 1999;83:1173.
11. Perera V, Bajorek BV, Matthews S, et al. The impact of frailty on the utilisation of antithrombotic therapy in older patients with atrial fibrillation. Age Ageing. 2009;38:156.
12. Wynne HA, Yelland C, Cope LH, et al. The association of age and frailty with the pharmacokinetics and pharmacodynamics of metoclopramide. Age Ageing. 1993;22:354.
13. Mitchell SJ, Hilmer SN, Murnion BP, et al. Hepatotoxicity of therapeutic short-course paracetamol in hospital inpatients: impact of ageing and frailty. J Clin Pharm Ther. 2011;36:327.
14. Crentsil V, Ricks MO, Xue QL, et al. A pharmacoepidemiologic study of community-dwelling, disabled older women: factors associated with medication use. Am J Geriatr Pharmacother. 2010;8:215.
15. Gnjidic D, Hilmer SN, Blyth FM, et al. High-risk prescribing and incidence of frailty among older community-dwellingmen. Clin Pharmacol Ther. 2012;91:521.
16. Gupta N, Salter M, Massie A, et al.Discordance BetweenMeasured Frailty and Provider Perceptions of Frailty. World Transplant Congress, San Francisco, CA. 2014.
17. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9:179.
18. Bandeen-Roche K, Xue QL, Ferrucci L, et al. Phenotype of frailty: characterization in the women's health and aging studies. J Gerontol A Biol Sci Med Sci. 2006;61:262.
19. Barzilay JI, Blaum C, Moore T, et al. Insulin resistance and inflammation as precursors of frailty: the Cardiovascular Health Study. Arch Intern Med. 2007;167:635.
20. Cappola AR, Xue QL, Fried LP. Multiple hormonal deficiencies in anabolic hormones are found in frail older women: the Women's Health and Aging Studies. J Gerontol A Biol Sci Med Sci. 2009;64:243.
21. Leng SX, Hung W, Cappola AR, et al. White blood cell counts, insulin-like growth factor-1 levels, and frailty in community-dwelling older women. J Gerontol A Biol Sci Med Sci. 2009;64:499.
22. Leng SX, Xue QL, Tian J, et al. Inflammation and frailty in older women. J Am Geriatr Soc. 2007;55:864.
23. Newman AB, Gottdiener JS, McBurnie MA, et al. Associations of subclinical cardiovascular disease with frailty. J Gerontol A Biol Sci Med Sci. 2001;56:M158.
24. Walston J, McBurnie MA, Newman A, et al. Frailty and activation of the inflammation and coagulation systems with and without clinical comorbidities: results from the Cardiovascular Health Study. Arch Intern Med. 2002;162:2333.
25. Xue QL, Bandeen-Roche K, Varadhan R, et al. Initial manifestations of frailty criteria and the development of frailty phenotype in the Women's Health and Aging Study II. J Gerontol A Biol Sci Med Sci. 2008;63:984.
26. Chang SS, Weiss CO, Xue QL, et al. Association between inflammatory-related disease burden and frailty: results from the Women's Health and Aging Studies (WHAS) I and II. Arch Gerontol Geriatr. 2012;54 : 9.
27. Chang SS, Weiss CO, Xue QL, et al. Patterns of comorbid inflammatory diseases in frail older women: the Women's Health and Aging Studies I and II. J Gerontol A Biol Sci Med Sci. 2010;65:407.
28. McAdams-Demarco MA, Law A, Salter M, et al. Frailty as a Novel Predictor of Mortality and Hospitalization in Hemodialysis Patients of All Ages. J Am Geriatr Soc. 2013;61:896.
29. McAdams-Demarco MA, Suresh S, Law A, et al. Frailty and falls among adult patients undergoing chronic hemodialysis: a prospective cohort study. BMC Nephrol. 2013;14:224.
30. Levey AS, Stevens LA, Schmid CH, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150:604.